Emibetuzumab (INN; development code LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer.Statement On A Nonproprietary Name Adopted By The USAN Council - Emibetuzumab, American Medical Association. It is in phase II trials for patients with non-small-cell lung cancer (NSCLC). This drug was developed by Eli Lilly & Company.
References